These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 18615170)
1. Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician. Upadhyaya HP Prim Care Companion J Clin Psychiatry; 2008; 10(3):211-21. PubMed ID: 18615170 [TBL] [Abstract][Full Text] [Related]
2. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Kollins SH Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709 [TBL] [Abstract][Full Text] [Related]
3. Irish adolescents with ADHD and comorbid substance use disorder. Edokpolo O; Nkire N; Smyth BP Ir J Psychol Med; 2010 Sep; 27(3):148-151. PubMed ID: 30282206 [TBL] [Abstract][Full Text] [Related]
4. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling RL Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941 [TBL] [Abstract][Full Text] [Related]
5. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder. Jain R; Katic A Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696 [TBL] [Abstract][Full Text] [Related]
6. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder]. Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296 [TBL] [Abstract][Full Text] [Related]
7. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. Upadhyaya HP J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378 [TBL] [Abstract][Full Text] [Related]
8. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Najib J Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715 [TBL] [Abstract][Full Text] [Related]
10. Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician. Barbuti M; Maiello M; Spera V; Pallucchini A; Brancati GE; Maremmani AGI; Perugi G; Maremmani I J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176536 [TBL] [Abstract][Full Text] [Related]
11. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications. Schubiner H CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Goldman LS; Genel M; Bezman RJ; Slanetz PJ JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570 [TBL] [Abstract][Full Text] [Related]
13. The potential for misuse and abuse of medications in ADHD: a review. Clemow DB; Walker DJ Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651 [TBL] [Abstract][Full Text] [Related]
14. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Klassen LJ; Bilkey TS; Katzman MA; Chokka P Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450 [TBL] [Abstract][Full Text] [Related]
15. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814 [TBL] [Abstract][Full Text] [Related]